AU592072B2 - Novel alkali and alkaline earth metal salts of alpha-(3- pentadecylphenoxy)-isobutyric acids and process for the preparation thereof - Google Patents
Novel alkali and alkaline earth metal salts of alpha-(3- pentadecylphenoxy)-isobutyric acids and process for the preparation thereof Download PDFInfo
- Publication number
- AU592072B2 AU592072B2 AU52474/86A AU5247486A AU592072B2 AU 592072 B2 AU592072 B2 AU 592072B2 AU 52474/86 A AU52474/86 A AU 52474/86A AU 5247486 A AU5247486 A AU 5247486A AU 592072 B2 AU592072 B2 AU 592072B2
- Authority
- AU
- Australia
- Prior art keywords
- pentadecylphenoxy
- isobutyric acid
- preparation
- calcium
- calcium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- -1 alkaline earth metal salts Chemical class 0.000 title claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 title description 4
- 239000003513 alkali Substances 0.000 title description 2
- SQSAOEAQCNWNBE-UHFFFAOYSA-N 2-methyl-2-(3-pentadecylphenoxy)propanoic acid Chemical class CCCCCCCCCCCCCCCC1=CC=CC(OC(C)(C)C(O)=O)=C1 SQSAOEAQCNWNBE-UHFFFAOYSA-N 0.000 title 1
- 159000000007 calcium salts Chemical class 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 3
- 230000001603 reducing effect Effects 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 235000010730 Ulex europaeus Nutrition 0.000 claims 1
- 240000003864 Ulex europaeus Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 102000004895 Lipoproteins Human genes 0.000 description 9
- 108090001030 Lipoproteins Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 9
- 229960001214 clofibrate Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000000055 hyoplipidemic effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000001949 anaesthesia Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000012754 cardiac puncture Methods 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN292/DEL/83A IN160141B (instruction) | 1983-05-09 | 1983-05-09 | |
| EP86303552A EP0244526A1 (en) | 1983-05-09 | 1986-05-09 | Novel hypolipidemic and hypocholesteremic compounds and their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5247486A AU5247486A (en) | 1987-07-23 |
| AU592072B2 true AU592072B2 (en) | 1990-01-04 |
Family
ID=36889077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU52474/86A Ceased AU592072B2 (en) | 1983-05-09 | 1986-01-20 | Novel alkali and alkaline earth metal salts of alpha-(3- pentadecylphenoxy)-isobutyric acids and process for the preparation thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4731474A (instruction) |
| EP (1) | EP0244526A1 (instruction) |
| JP (1) | JPS62185046A (instruction) |
| AU (1) | AU592072B2 (instruction) |
| IN (1) | IN160141B (instruction) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5544255A (en) * | 1994-08-31 | 1996-08-06 | Peripheral Vision Limited | Method and system for the capture, storage, transport and authentication of handwritten signatures |
| WO2015176153A1 (en) * | 2014-05-23 | 2015-11-26 | The Governing Council Of The University Of Toronto | Ppar modulators |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU427159B2 (en) * | 1969-08-14 | 1972-08-15 | Parke, Davis & Company | 2,2 dimethyl-w-aryloxy alkanoic acids and the salts and esters thereof |
| AU511212B2 (en) * | 1976-10-18 | 1980-07-31 | Paul Kauser-Chepharin, Chemische-Pharmazeutische Industriegesellschaft | Process for producing Mg salt ofp-Chlorophenoxyisobutyric acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) * | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| IT1141655B (it) * | 1980-02-12 | 1986-10-08 | Schiapparelli Spa | Nuovi derivati dell'acido propanoico ad attivita' ipolipidemica e ipocolesterolemica |
-
1983
- 1983-05-09 IN IN292/DEL/83A patent/IN160141B/en unknown
-
1986
- 1986-01-17 US US06/820,410 patent/US4731474A/en not_active Expired - Fee Related
- 1986-01-20 AU AU52474/86A patent/AU592072B2/en not_active Ceased
- 1986-02-05 JP JP61023670A patent/JPS62185046A/ja active Pending
- 1986-05-09 EP EP86303552A patent/EP0244526A1/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU427159B2 (en) * | 1969-08-14 | 1972-08-15 | Parke, Davis & Company | 2,2 dimethyl-w-aryloxy alkanoic acids and the salts and esters thereof |
| AU511212B2 (en) * | 1976-10-18 | 1980-07-31 | Paul Kauser-Chepharin, Chemische-Pharmazeutische Industriegesellschaft | Process for producing Mg salt ofp-Chlorophenoxyisobutyric acid |
Also Published As
| Publication number | Publication date |
|---|---|
| IN160141B (instruction) | 1987-06-27 |
| EP0244526A1 (en) | 1987-11-11 |
| AU5247486A (en) | 1987-07-23 |
| JPS62185046A (ja) | 1987-08-13 |
| US4731474A (en) | 1988-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4137322A (en) | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents | |
| DE69815852T2 (de) | Neue schilddrüsenrezeptorliganden und verfahren | |
| DE2927715C2 (instruction) | ||
| DE3715809A1 (de) | Tetrahydronaphthalinderivate | |
| IE49902B1 (en) | 4-substituted-3-hydroxy-3-pyrroline-2,5-dione compounds,process for their preparation and pharmaceutical compositions containing the same | |
| US4732998A (en) | Bisphosphonic acids and esters | |
| US4309442A (en) | Method for controlling fertility in mammals | |
| DE3318989C2 (de) | ß,gamma-Dihydropolyprenylalkoholderivate und diese enthaltende Arzneimittel und deren Verwendung | |
| DE2317019A1 (de) | Neue 4,5-didehydro-prostaglandine | |
| DE2556474C2 (de) | Substituierte p-Benzyloxyphenylessigsäuren, ihre Herstellung sowie diese enthaltende Arzneimittel | |
| US4169103A (en) | Nonatetraenoic acid derivatives | |
| CA1267141A (fr) | Esters et amides de l'acide eicosatrynoique et leur application en pharmacie et en cosmetique | |
| AU592072B2 (en) | Novel alkali and alkaline earth metal salts of alpha-(3- pentadecylphenoxy)-isobutyric acids and process for the preparation thereof | |
| EP0133935B1 (de) | p-Oxibenzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln mit hypolipämischer Wirkung | |
| US4428959A (en) | 4-Alkylsubstituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | |
| GB1583691A (en) | Benzopyrans | |
| KR100224330B1 (ko) | 골관절 질환의 치료에 유용한 n-((4,5-디히드록시-및 4,5,8-트리히드록시-9,10-디히드로-9,10-디옥소-2-안트라센-일)카르보닐)아미노산 | |
| DE1493933A1 (de) | Beta-(Naphthyl-1)-isobuttersaeuren und Verfahren zu deren Herstellung | |
| DE2928594C2 (de) | 3-Hydroxy-4-(hydroxymethyl)-benzoesäure, deren Salze, Hydrate und Hydratsalze, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2330905A1 (de) | Verfahren zur herstellung von neuen 11-deoxyprostaglandinen der e- und freihen | |
| US4163859A (en) | Phenoxyldialkyl acetic acids and esters | |
| US4252947A (en) | Novel quinazolinone | |
| US3558645A (en) | 2-(4-(4',5-diphenyl - 2 - imidazolyl)-phenoxy) lower aliphatic monocarboxylic acids | |
| US3153050A (en) | Spiro | |
| EP0474358A2 (en) | Use of conduritol to inhibit an increase in blood sugar level |